Literature DB >> 35218384

Risk factors for residual dizziness in patients with benign paroxysmal positional vertigo after successful repositioning: a systematic review and meta-analysis.

Yujie Ke1, Xin Ma1, Yuanyuan Jing1, Tongxiang Diao1, Lisheng Yu2.   

Abstract

PURPOSE: To investigate the risk factors for residual dizziness (RD) in patients with benign paroxysmal positional vertigo (BPPV) after successful repositioning.
METHODS: Searches were performed in PubMed, Embase, Cochrane library, Web of Science, Chinese National Knowledge Infrastructure, and Sino Med up to March 7, 2021 and references of relevant articles were screened. Data from eligible studies were meta-analyzed using Stata version 16.0 and Review Manager 5.4.
RESULTS: In this systematic review and meta-analysis of 4487 patients from 31 studies, the prevalence of RD was 43.0% (95% CI 39.0-48.0%). Age (MD 4.17; 95% CI 2.13-6.21, P = 0.000), female gender (OR = 1.28, 95% CI 1.11-1.47, P = 0.001), secondary BPPV (OR 1.88; 95% CI 1.27-2.77, P = 0.001), a longer duration of BPPV before treatment (MD 3.45; 95% CI 1.87-5.02, P = 0.000), abnormal ocular vestibular evoked myogenic potential (OVEMP, OR 4.34; 95% CI 2.78-6.78, P = 0.000), abnormal cervical vestibular evoked myogenic potential (CVEMP, OR 2.48; 95% CI 1.54-3.99, P = 0.000), higher Dizziness Handicap Index (DHI) score before treatment (MD 10.88; 95% CI 5.96-15.80, P = 0.000), anxiety (OR 9.58; 95% CI 6.32-14.52, P = 0.000), osteopenia (OR = 4.40, 95% CI 2.17-8.96, P = 0.000), onset in winter (OR 7.27; 95% CI 2.38-22.24, P = 0.001) and with a history of BPPV (OR 1.79; 95% CI 1.06-3.04, P = 0.03) are the risk factors for RD in patients with BPPV after successful repositioning. The affected side, location or type of semicircular involvement, hyperlipidemia, diabetes, hypertension, heart disease, migraine, sleep disorders, canalolithiasis/cupulolithiasis, the number of times the canalith repositioning procedures (CRPs) were performed and number of vertigo attacks did not correlate with the occurrence of RD.
CONCLUSIONS: Despite successful treatment, nearly half of the BPPV patients developed RD. RD seems to be a syndrome caused by multiple factors. The pathogenesis of most factors can be explained by psychological and/or physical disorders. Early recognition of these risk factors contributes to the prevention and treatment of RD.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  After; Benign paroxysmal positional vertigo; Meta-analysis; Residual dizziness; Risk factors; Successful

Mesh:

Year:  2022        PMID: 35218384     DOI: 10.1007/s00405-022-07288-9

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  48 in total

1.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.

Authors:  Andreas Stang
Journal:  Eur J Epidemiol       Date:  2010-07-22       Impact factor: 8.082

Review 2.  Practice parameter: therapies for benign paroxysmal positional vertigo (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  T D Fife; D J Iverson; T Lempert; J M Furman; R W Baloh; R J Tusa; T C Hain; S Herdman; M J Morrow; G S Gronseth
Journal:  Neurology       Date:  2008-05-27       Impact factor: 9.910

3.  Anxiolytics reduce residual dizziness after successful canalith repositioning maneuvers in benign paroxysmal positional vertigo.

Authors:  Hahn Jin Jung; Ja-Won Koo; Chong Sun Kim; Ji Soo Kim; Jae-Jin Song
Journal:  Acta Otolaryngol       Date:  2011-12-27       Impact factor: 1.494

Review 4.  Benign Paroxysmal Positional Vertigo: What We Do and Do Not Know.

Authors:  Daniele Nuti; David S Zee; Marco Mandalà
Journal:  Semin Neurol       Date:  2020-01-14       Impact factor: 3.420

5.  Clinical Practice Guideline: Benign Paroxysmal Positional Vertigo (Update).

Authors:  Neil Bhattacharyya; Samuel P Gubbels; Seth R Schwartz; Jonathan A Edlow; Hussam El-Kashlan; Terry Fife; Janene M Holmberg; Kathryn Mahoney; Deena B Hollingsworth; Richard Roberts; Michael D Seidman; Robert W Prasaad Steiner; Betty Tsai Do; Courtney C J Voelker; Richard W Waguespack; Maureen D Corrigan
Journal:  Otolaryngol Head Neck Surg       Date:  2017-03       Impact factor: 3.497

6.  Prevalence and management of post-BPPV residual symptoms.

Authors:  Cristina Vaduva; Jonathan Estéban-Sánchez; Ricardo Sanz-Fernández; Eduardo Martín-Sanz
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-04-23       Impact factor: 2.503

Review 7.  Diagnosis and management of benign paroxysmal positional vertigo (BPPV).

Authors:  Lorne S Parnes; Sumit K Agrawal; Jason Atlas
Journal:  CMAJ       Date:  2003-09-30       Impact factor: 8.262

8.  Autonomic dysfunction as a possible cause of residual dizziness after successful treatment in benign paroxysmal positional vertigo.

Authors:  Hyun-Ah Kim; Hyung Lee
Journal:  Clin Neurophysiol       Date:  2013-09-14       Impact factor: 3.708

Review 9.  Clinical practice guideline: benign paroxysmal positional vertigo.

Authors:  Neil Bhattacharyya; Reginald F Baugh; Laura Orvidas; David Barrs; Leo J Bronston; Stephen Cass; Ara A Chalian; Alan L Desmond; Jerry M Earll; Terry D Fife; Drew C Fuller; James O Judge; Nancy R Mann; Richard M Rosenfeld; Linda T Schuring; Robert W P Steiner; Susan L Whitney; Jenissa Haidari
Journal:  Otolaryngol Head Neck Surg       Date:  2008-11       Impact factor: 3.497

10.  Observational study on risk factors determining residual dizziness after successful benign paroxysmal positional vertigo treatment: the role of subclinical BPPV.

Authors:  F Dispenza; W Mazzucco; S Mazzola; F Martines
Journal:  Acta Otorhinolaryngol Ital       Date:  2019-10       Impact factor: 2.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.